Ekso Bionics 2025 Q2 Earnings Misses Targets as Net Loss Widens 12%

Ekso Bionics (EKSO) reported its fiscal 2025 Q2 earnings on July 28th, 2025. The company's financial performance fell short of expectations, with significant revenue declines and a widened net loss. Despite ongoing challenges, leadership remains optimistic about future recovery, particularly in the Personal Health segment, which has shown promising growth. The guidance for the year-end suggests potential improvements, driven by anticipated sales closures and strategic initiatives.

Revenue
Ekso Bionics reported a steep 58.4% drop in total revenue for Q2 2025, amounting to $2.06 million compared to $4.95 million in Q2 2024. Device revenue contributed $1.17 million, while service and support accounted for $712,000. Subscriptions added $99,000, complemented by parts and other segments bringing in $74,000. This comprehensive downturn underscores the challenges faced in their Enterprise Health sales, although Personal Health devices showed growth.

Earnings/Net Income
Ekso Bionics reported a net loss widening to $2.71 million in Q2 2025, increasing by 12.1% from the previous year. The loss per share improved to $1.24 from $1.99 due to a change in share count. Despite narrowing losses per share, EPS remains challenging, reflecting ongoing financial difficulties.

Price Action
The stock price of Ekso Bionics experienced significant fluctuations recently, dropping 11.87% on the latest trading day, yet rising 14.39% over the full week. Month-to-date, the stock saw a substantial increase of 43.81%.

Post-Earnings Price Action Review
The strategy of purchasing Ekso Bionics shares post-revenue increase and holding them for 30 days has resulted in substantial losses over the past three years. This approach yielded a return of -97.03%, sharply underperforming the benchmark by 185.77%. The strategy's Sharpe ratio stood at -0.55, highlighting significant downside risk. Despite the maximum drawdown being recorded at 0%, suggesting potential liquidation at some point, this behavior is atypical in usual market conditions. The analysis highlights the necessity for cautious evaluation of investment strategies and emphasizes the importance of considering market volatility.

CEO Commentary
Scott G. Davis, CEO & Director, expressed disappointment in Q2 revenues due to delays in multi-device Enterprise Health sales. However, he remains optimistic about recovery by year-end, citing a $1 million order expected in Q3. Davis highlighted promising growth in Personal Health, with a more than 50% increase in the first half of 2025, and anticipates this segment will contribute significantly to future revenue, potentially overtaking Enterprise Health by 2027.

Guidance
Ekso Bionics expects to close a substantial portion of deferred Enterprise Health sales by year-end, aiming for a revenue recovery in the latter half of 2025. The company projects Personal Health revenues to account for 25% of total revenue by year-end, with expectations of surpassing Enterprise Health sales by 2027. Despite current net losses, the guidance indicates a strategic path toward growth.

Additional News
Ekso Bionics recently announced acceptance into the NVIDIA Connect program, aiming to develop AI capabilities across its device portfolio. This strategic collaboration is expected to enhance product differentiation. The company also launched eksoUniversity, a virtual platform for continuing education targeted at physical therapists, which underscores their commitment to advancing neurological rehabilitation. These initiatives represent Ekso Bionics’ efforts to expand its market reach and reinforce its position as a leader in exoskeleton technology.